$ACRV DOWN 58% SINCE THIS NEWS! OVER REACTION? SELLING ON

New Post Public Reply Private Reply Replies (0) Message Board
trooperstocks
56
$ACRV DOWN 58% SINCE THIS NEWS! OVER REACTION? SELLING ON NEWS? PLEASE DISCUSS. GREAT OPPORTUNITY IN BIOTECH SECTOR:

Janaury 9th CLOSE $1.75 DOWN 66% YTD #BULLISH #INVESTORS #FDAApproval #CANCER #RESEARCH #TUMOR #SHRINKAGE #ACRIVON https://acrivon.com

#BIOTECH NEWS: "Acrivon Therapeutics, Inc. Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11" (Nasdaq: ACRV)

Key highlights:

*Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy*

*Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects

*Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low dose gemcitabine (ULDG) as a tumor sensitizer and enrollment completion expected in fourth quarter 2026

*Based on preclinical AP3 data showing strong synergy between ACR-368 and anti-PD-L1, company has submitted a Phase 3 confirmatory protocol to the FDA for ACR-368 plus anti-PD-1 therapy in frontline EC subjects; global trial readiness expected mid-2026

*Initial data from Phase 1 dose escalation (N=33) for ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, showed favorable tolerability; two weekly oral dosing regimens (160 mg QD, 3d on/4d off and 240 mg QD, 2d on/5d off) established with a bi-weekly regimen initiated

*Tumor shrinkage was observed at ≥120 mg dose level in 9/20 subjects, including a confirmed PR in EC, and unconfirmed PRs in SCLC and sqNSCLC, two tumor types predicted sensitive by AP3, not previously shown sensitive to WEE1 inhibitors in development

*ACR-6840, a potential first-in-class AP3-derived oral CDK11 inhibitor, nominated as next preclinical development candidate, with IND submission planned for fourth quarter 2026

Read more on http://Nasdaq.com: https://nasdaq.com/press-release/acrivon-ther...r-clinical
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Children's Institute Gala Raises $4M: A Night to Remember

Updated Category News Views 42

Breaking Records and Honoring Legends You know, sometimes there's more to the world than stocks and ticker tapes. Over in Los Angeles, the Children's Institute pulled off a real spectacle with their Annual Cape & Gown Gala, drawing in more than 600 folks and raking in a whopping $4 million. That's right, four million clams in one evening—a record-breaker for them. When...

Continue Reading
BMZ's RB-900 E-Bike Battery Shakes Up U.S. Market

Updated Category News Views 58

A New Ride: BMZ's Strategic Move Look, the e-bike world isn't just pedaling; it's racing ahead, and BMZ Battery Solutions Group is shifting gears. From November 11–12, 2026, the company's going to stir the pot at Micromobility America, introducing its POWER2RIDE RB-900 e-bike battery—a powerhouse eager to make its mark in the U.S. e-bike scene. We're talking real...

Continue Reading
Unquiet Nights' New Tune Echoes Rome's Eternal Lingering

Updated Category News Views 15

Irish Rockers Unquiet Nights Celebrate a Poignant Release Ever heard of a band that takes its darn sweet time? Well, Unquiet Nights just dropped a single after sitting on it for a solid 15 years. 'Last Days of Rome' isn’t just a new tune; it’s a love letter to both music and the eternal echoes of Rome’s history. These Belfast rockers have been crafting this piece...

Continue Reading
ASMAX Unleashes Next-Level Motorcycle Comms at EICMA

Updated Category News Views 141

Transforming the Motorcycle Communication Landscape Motorcycling ain't just about the roaring engines and the rubber on the road. In the world of helmets and handlebars, some bright minds are weaving tech magic at the EICMA 2026 in Milan. ASMAX has rolled out its shiny new RoamX intercom gadget, leaving folks buzzing at Hall 6. What RoamX Brings to the Table This ain't...

Continue Reading
Ritz-Carlton Yacht Collection Sets Sail with New Leaders

Updated Category News Views 19

Charting New Waters in Luxury Cruising Change is cruising on the open sea, folks—captained by Alan Leibman and Tatiana Ferreira, who're now at the helm of The Ritz-Carlton Yacht Collection. These names aren't just flotsam in the breeze; they're packing as much pedigree as you'd find in a top-shelf bottle of Champagne. They aren't steering yachts for a joyride; the...

Continue Reading
Leatt Gears Up for Q3 Results Conference Call

Updated Category News Views 50

A good heads-up, folks, isn't just about keeping helmets snug—it’s about knowing when to cash in, especially when Leatt Corporation's got their Q3 results ready to drop. November 12 is the big day, so circle that on your calendars. They're rolling out the numbers before the market even gets its coffee, possibly nudging the ticker, OTCQB:LEAT, in a ripple you’ll want...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 240

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Chipotle's BOGO Promo Returns: Tattoos Boost Sales

Updated Category News Views 26

Chipotle's BOGO Charade: A Tattooed Affair You've got to hand it to Chipotle—they know how to turn heads and wallets with their quirky promotions. The upcoming 'Tatted Like a Chipotle Bag' offer is a prime example of how they ride the cultural zeitgeist as they gear up for another record-breaking day on Friday, November 13. And seriously, with tattoos in play, they're...

Continue Reading
Outer Spaces Unveils OS1 at Major Energy Expo

Updated Category News Views 32

Introduction to the Future of Solar Living Just when you thought you'd seen it all, along comes Outer Spaces with their OS1—a solar pavilion and battery deck that looks at residential energy with fresh eyes. Debuting at the RE+ 2026 in Las Vegas, this isn't just another gizmo. This is about bringing solar power to your backyard without making your roof look like it...

Continue Reading
Century Lithium's Angel Island Project Nears NEPA Review

Updated Category News Views 39

Sometimes the gears of progress grind slowly, but that's part of the deal in the mining game. For Century Lithium Corp., the completion of the Mine Plan of Operations (PoO) for the Angel Island Project marks a big step forward—or at least, it gets them ready for the next round of bureaucratic wrangling under the NEPA. Let's dissect what this means as they march toward...

Continue Reading

Top 5 Most Recently Viewed Articles

USA Rare Earth Prepares for Q1 2025 Results and Call

Updated Category News Views 364

Upcoming Financial Results Announcement USA Rare Earth, Inc. (Nasdaq: USAR) is gearing up to unveil its financial performance for the first quarter of 2025. Investors and stakeholders can look forward to the results being released after U.S. markets close on May 14, 2025. This marks an important date for the company as they reflect on their financial journey during the...

Continue Reading
Innovative Prostate Cancer Trial Launches with TLX591 in Miami

Updated Category News Views 111

Telix Pharmaceuticals Initiates Groundbreaking Trial Telix Pharmaceuticals Limited (NASDAQ: TLX) has taken exciting steps in prostate cancer treatment with the commencement of the ProstACT Global Phase 3 clinical trial. This innovative trial is taking place at the Biogenix Molecular Research Center, focusing on TLX591, a novel radiopharmaceutical designed for patients...

Continue Reading
Alstom S.A. Reports on Half-Year Liquidity for 2024

Updated Category News Views 266

Overview of Alstom's Liquidity Statement As part of its ongoing commitment to transparency and reporting, Alstom S.A. recently published its half-year liquidity contact statement. This statement reflects the company's financial health and activities surrounding its liquidity contract with Rothschild Martin Maurel. As of the end of the previous fiscal period, Alstom...

Continue Reading
Vulcan Materials Company: Strong 2024 Financial Performance

Updated Category News Views 538

Vulcan Materials Company Reports Exceptional Financial Results Vulcan Materials Company (NYSE: VMC), recognized as the largest producer of construction aggregates in the United States, has published its outstanding financial results for the 2024 fiscal year. The company has demonstrated remarkable execution, resulting in significant margin expansion and growth in...

Continue Reading
Local Logic and BHS Join Forces to Transform Real Estate

Updated Category News Views 254

Local Logic and Brown Harris Stevens Form Strategic Alliance In an exciting development within the real estate sector, Local Logic, a top-tier location intelligence company, has announced a strategic partnership with Brown Harris Stevens (BHS), a leader in the luxury real estate market. This collaboration signifies a shared commitment to leveraging groundbreaking...

Continue Reading